Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GPR4 | P46093 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5689825 | 0.92 | KCNH2 (0.42) | GRIN2BMGLLKMT2ANPY2RGAA | |
| SCHEMBL5687857 | 0.91 | GRIN2B (0.41) | GRIN2BMGLLGPR4NPY2RGAA | |
| SCHEMBL5687207 | 0.87 | KMT2A (0.55) | KMT2AGAAKCNH2 | |
| SCHEMBL5688253 | 0.86 | GRIN2B (0.43) | GRIN2BMGLLKMT2ANPY2RGAA | |
| SCHEMBL5690385 | 0.85 | LIPE (0.45) | GRIN2BMGLLGPR4NPY2RLIPE | |
| SCHEMBL5687622 | 0.85 | LIPE (0.48) | GRIN2BMGLLGPR4LIPE | |
| SCHEMBL5687917 | 0.84 | GRIN2B (0.44) | GRIN2BNPY2RKCNH2SSTR5CHEK2 | |
| SCHEMBL5687640 | 0.84 | GRIN2B (0.43) | GRIN2BMGLLNPY2RKCNH2SSTR5 | |
| SCHEMBL5931434 | 0.83 | GRIN2B (0.41) | GRIN2BMGLLNPY2RGAALIPE | |
| SCHEMBL5687429 | 0.82 | GRIN2B (0.46) | GRIN2BMGLLNPY2RGAAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| CN-1805951-A | Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase | NOVO NORDISK AS (DK) | 2006-07-19 | — | — | CN | claimed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| US-20060160851-A1 | Substituted piperidine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| CN-1805951-A | Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase | NOVO NORDISK AS (DK) | 2006-07-19 | — | — | CN | disclosed |
| EP-1636207-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111032-A1 | SUBSTITUTED PIPERIDINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160851-A1 | Substituted piperidine carbamates | LIPE, PNLIP, LIPC | GRIN2B 2588/4885MGLL 39/4885KMT2A 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.